Abstract: Objective To investigate the clinical application of platelet vascular endothelial growth factor（VEGF）and TSP-1 determination in the progression of lung cancers. Methods The levels of VEGF and TSP-1 in platelets and platelet-poor plasma（PPP）in 71 patients with lung cancers and 35 healthy controls were determined by ELISA method. Results The levels of platelet VEGF and VEGF/TSP-1 in patients with unmetastatic lung cancers and metastatic lung cancers were significantly higher than those in healthy controls （P<0.05）; the levels of platelet VEGF and VEGF/TSP-1 in patients with metastatic lung cancers were significantly higher than those in patients with unmetastatic lung cancers （P<0.05）. Moreover,the levels of platelet TSP-1 in patients with unmetastatic lung cancers and metastatic lung cancers were remarkably lower than those in healthy controls （P<0.05）. However,the PPP VEGF and TSP-1 in the patients and control group were undetactable （<7.18 pg/ml）. Conclusions The balance between the levels of VEGF and TSP-1 is shifted in the peripheral blood of patients with lung cancers,and the levels of platelet VEGF and VEGF/TSP-1 will help to reflect the progression of lung cancers.

Key words: Lung cancer, VEGF TSP-1, Platelet